← Back

Symbiotix Biotherapies, Inc. announces Phase 1 STTR Award from National Institute of Allergy and Infectious Diseases (NIAID)

Boston, MA – March 1, 2014 – Symbiotix Biotherapies, Inc. (“Symbiotix”) today announced that it was awarded a Phase 1 STTR from NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Symbiotix’ lead clinical candidate, Polysaccharide A (PSA), is the first molecule to emerge from the microbiome, and the $323,000 award from NIH enables the completion of important translational studies related to further evaluation of PSA as a novel therapeutic treatment for multiple sclerosis (MS). PSA is a first-in-class oral therapy that works through a novel mechanism of action related to activation of regulatory T cells, which exert an antiinflammatory effect through the production of IL-10. “MS is a chronic debilitating inflammatory disease of the centeral nervous system that afflicts nearly 500,000 individuals in the US alone for which there is no cure. Current therapies offer partial benefit for reduction of relapses and time to disability. However, all of these FDA approved treatments have side effects some of which can be rather profound” said Prof. Lloyd Kasper, Professor of Medicine, Microbiology and Immunology at Geisel School of Medicine at Dartmouth College, and Co-Founder of Symbiotix. “PSA promises to be a safe and effective new therapy for the many patients with this disease that will be delivered by oral administration and anticipated to have few, if any, significant side effects as it is derived from a commensal bacterial molecule that colonizes most of humankind”. The studies funded through this prestigious award will be conducted by Symbiotix in collaboration with the Geisel School of Medicine at Dartmouth College.

“Symbiotix is thrilled to have received our Company’s first NIH award, and honored to have the validation and support of NIH as we advance our development program for PSA, which promises to bring an entirely new strategy for treating devastating immune-mediated diseases such as multiple sclerosis,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of Symbiotix.

About Symbiotix Biotherapies, Inc.

Symbiotix Biotherapies, Inc. was founded on the basis of over a decade of research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology and Dartmouth College, and our Company’s scientific founders are distinguished thought leaders in the microbiome field. At Symbiotix, we are developing a novel class of molecular therapeutics based on molecules derived from the human microbiome. Our lead program represents the first molecule to emerge from the human microbiome, and is a first-in-class oral agent for the treatment of serious immune-mediated diseases. For more information, please visit www.symbiotix-bio.com.